| A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer |
28 |
| Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review |
24 |
| Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography |
21 |
| Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for Lu-177-labelled PSMA Radioligand Therapy |
20 |
| Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer |
19 |
| Performance of the Bladder EpiCheck (TM) Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial |
17 |
| Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naive Men |
16 |
| Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes |
16 |
| Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Meta-analysis of Oncologic, Perioperative, and Complication-related outcomes |
16 |
| What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review |
16 |
| Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer |
16 |
| Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients |
15 |
| The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy |
15 |
| Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer |
14 |
| Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States |
14 |
| Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer |
14 |
| First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis |
14 |
| Role of Active Surveillance for Localized Small Renal Masses |
14 |
| Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer |
13 |
| Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma |
13 |
| A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer |
13 |
| Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? |
13 |
| Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer |
13 |
| Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review |
12 |
| Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review |
12 |
| Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial |
11 |
| Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA |
11 |
| Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies |
11 |
| Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis |
11 |
| Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies |
11 |
| Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
10 |
| Staging the Host: Personalizing Risk Assessment for Radical Cystectomy Patients |
10 |
| Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial |
10 |
| Prostate Cancer Risk Assessment in Biopsy-naive Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy |
9 |
| Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer |
9 |
| Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy |
9 |
| Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes |
9 |
| Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial |
9 |
| From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma |
9 |
| Frailty and Greater Health Care Resource Utilization Following Major Urologic Oncology Surgery |
9 |
| Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease |
8 |
| Four-point Peritoneal Flap Fixation in Preventing Lymphocele Formation Following Radical Prostatectomy |
8 |
| Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer |
8 |
| Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response |
8 |
| Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases |
8 |
| Role of Checkpoint Inhibition in Localized Bladder Cancer |
8 |
| Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy |
8 |
| Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer |
7 |
| Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide |
7 |
| Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer |
7 |
